share_log

Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics

Benzinga ·  Jun 13 00:09

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment